Human tissue derived compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-11318168-B2
Application number	US-201715631707-A
Country	US
Kind code	B2
Filing date	Jun 23, 2017
Priority date	Jun 24, 2016
Publication date	May 3, 2022
Grant date	May 3, 2022

Abstract

Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

First claim

We claim:

1. A composition comprising a non-homogenized chorionic matrix, a devitalized homogenized amniotic matrix, and a devitalized homogenized umbilical cord (UC) matrix, wherein the non-homogenized chorionic matrix comprises native cells, wherein the composition is lyophilized, and wherein at least 70% of the native cells of the non-homogenized chorionic matrix are viable after storage at room temperature in the lyophilized state, and wherein the native cells are not culturally expanded after lyophilization.

2. The of claim 1 , further comprising a viscous modifier.

3. The composition of claim 1 further comprising viable, isolated amniotic cells.

4. The composition of claim 1 , further comprising a scaffold.

5. The composition of claim 1 , wherein the homogenized amniotic matrix and/or the homogenized UC matrix are not decellularized.

6. The composition of claim 1 , wherein the non-homogenized chorionic matrix is minced.

7. The composition of claim 1 , wherein the composition comprises viable chorionic stem cells, amniotic stem cells, fibroblasts, epithelial cells or a combination thereof.

8. The composition of claim 1 , wherein the homogenized amniotic matrix and homogenized UC matrix are derived from the same donor.

9. The composition of claim 1 , wherein the nonhomogenized chorionic matrix and homogenized amniotic matrix are from the same donor.

10. The composition of claim 1 , wherein the nonhomogenized chorionic matrix and homogenized UC matrix are from the same donor.

11. The composition of claim 1 , wherein the homogenized UC matrix comprises de-veined UC tissue.

12. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Osiris Therapeutics Inc

Inventors

• Sinclair Steven Michael
• Danilkovitch Alla
• Sathyamoorthy Malathi
• Kuang Jin-Qiang
• Dhall Sandeep
• Liu Yishan
• Melchiorri Anthony John
• Moorman Matthew Robert
• Lo Moriello Mena Schiano
• Lerch Anne Allgood

Classifications

• A61K35/50 Primary

  Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61L26/0057

  Ingredients of undetermined constitution or reaction products thereof · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title

• A61L27/3834

  Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title